SAN DIEGO, June 19, 2013 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation against Dynavax Technologies Corporation (DVAX) concerning possible violations of federal securities laws. The investigation will focus on whether Dynavax issued materially false and misleading statements in order to artificially inflate the Company's share price.
On June 10, 2013, Dynavax announced that the U.S. Food and Drug Administration was requiring additional safety data on Heplisav, Dynavax's investigational adult hepatitis B vaccine. In addition, the FDA cited manufacturing concerns in its response letter. On the news, the price of Dynavax shares declined by over 40%.
If you have information that could assist in this investigation or if you are a Dynavax shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker, the firm's lead fraud investigator at firstname.lastname@example.org or 619-230-0063.
Johnson & Weaver, LLP is a nationally recognized shareholders' rights law firm. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com.
CONTACT: Johnson & Weaver, LLP Jim Baker, Lead Fraud Investigator 619-230-0063 Ext. 118 email@example.comSource:Johnson & Weaver, LLP